Home » Topics » Disease categories and therapies » Urology

Urology
RSS

Rolling NDA commences for Lucassin in hepatorenal syndrome type 1

May 29, 2008

FDA accepts for filing Watson's NDA for oxybutynin chloride topical gel for overactive bladder

May 29, 2008

PNU-165442G improves stress urinary incontinence in women in phase II study

May 27, 2008

Indevus licenses Canadian rights for Sanctura XR to Allergan

May 23, 2008

Omeros initiates patient enrollment in phase I OMS-201 study

May 22, 2008

Protox initiates dosing in phase II clinical trial of PRX-302 in BPH

May 19, 2008

AEterna Zentaris initiates dosing in phase III safety trial of cetrorelix in BPH

May 16, 2008

Recent Astellas patent describes new compounds for treating urinary incontinence

May 14, 2008

BMP receives SFDA acceptance for Enablex clinical trial

May 9, 2008

Nymox announces that 3 year follow-up study of NX-1207 for BPH is near completion

May 8, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...